Upgrade to SI Premium - Free Trial

Leerink Partners on Hims and Hers (HIMS): FDA meeting to discuss peptide restrictions 'clear positive,' could fill growth hole

April 16, 2026 11:11 AM
Leerink Partners analyst Michael Cherny reiterated a Market Perform rating and $25.00 price target on Hims and Hers (NYSE: HIMS)The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments